8-K: Personalis Reports 15% Revenue Growth for Full Year 2024, Driven by Pharma Partnerships and Strategic Investment from Merck

Personalis, Inc. announces its fourth quarter and full year 2024 financial results, highlighting a 15% increase in full-year revenue and a strategic investment from Merck.

Summary

• Personalis, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Full year revenue reached $84.6 million, a 15% increase compared to $73.5 million in 2023.
• The company delivered 1,441 total molecular tests in Q4 2024, a 52% increase from the previous quarter.
• For the full year, Personalis delivered 3,285 molecular tests, significantly up from 177 in 2023.
• A $50 million direct investment was secured from Merck Sharp & Dohme LLC.
• Personalis extended its multi-year agreement with ModernaTX, Inc.
• The company expanded its commercial agreement with Tempus AI, Inc.
• Net loss for the full year was $81.3 million, or $1.37 per share, compared to a net loss of $108.3 million, or $2.25 per share, in 2023.
• Cash, cash equivalents, and short-term investments totaled $185.0 million as of December 31, 2024.
• For Q4 2024, revenue was $16.8 million, a 15% decrease compared to $19.7 million in Q4 2023.
• Net loss for Q4 2024 was $16.4 million, or $0.23 per share, compared to a net loss of $26.6 million, or $0.54 per share, in Q4 2023.
• Personalis anticipates Q1 2025 revenue to be between $17 and $18 million.
• The company projects full year 2025 revenue to be in the range of $80 to $90 million.
• Personalis expects a net loss of approximately $85 million for the full year 2025.
• Cash usage is projected to be between $75 and $80 million for 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company shows revenue growth and strategic partnerships, the projected net loss and increased cash usage for 2025 temper the overall outlook.

Positives

• Full year revenue increased by 15% to $84.6 million.
• Molecular test deliveries saw a substantial increase, with a 52% rise in Q4 2024 compared to Q3 2024.
• The company secured a $50 million direct investment from Merck.
• Personalis expanded its partnerships with Moderna and Tempus, indicating strong industry validation.
• Net loss decreased from $108.3 million in 2023 to $81.3 million in 2024, showing improved financial performance.
• Cash usage from operations and capital equipment additions decreased in 2024 to $46.8 million, compared with $67.2 million.

Negatives

• Revenue for the fourth quarter of 2024 decreased by 15% compared to the fourth quarter of 2023, primarily due to declines in revenue from Natera and the VA MVP.
• Net loss for Q4 2024 was $16.4 million, compared to a net loss of $26.6 million in Q4 2023.
• The company projects a net loss of approximately $85 million for the full year 2025.
• Cash usage is projected to increase to between $75 and $80 million for 2025.

Risks

• The company's future performance is subject to risks related to the timing and pace of new orders from customers, including Moderna, Merck, and VA MVP.
• The success of Personalis' clinical sales teams and Tempus' sales and marketing efforts could impact revenue.
• The timing of tissue, blood, and other specimen sample receipts from customers can materially impact revenue.
• The company's ability to obtain Medicare coverage and reimbursement is uncertain.
• The company's gross margin is expected to be lower in 2025 (21% to 23%) compared to 2024 (32%) due to investments in driving clinical usage ahead of reimbursement.

Future Outlook

Personalis expects total company revenue to be in the range of $80 to $90 million for the full year of 2025, with a net loss of approximately $85 million and cash usage in the range of $75 to $80 million.

Management Comments

• 'In 2024, we executed very well and are starting 2025 confident our strategy is working and we will Win in MRD,' said Chris Hall, Chief Executive Officer and President.
• Chris Hall also noted that the company expanded its partnership with Tempus, presented compelling clinical data, and drove testing growth 52% quarter over quarter ending the year with 1,441 molecular tests in the fourth quarter.
• Hall stated that the long-term commercial collaboration with Moderna and the strategic investment of $50 million from Merck endorse the company's technology platform and capabilities and provide a pathway to cashflow break-even.

Industry Context

Personalis' focus on precision oncology and MRD testing aligns with the growing trend of personalized medicine in cancer treatment. The collaborations with major players like Merck and Moderna highlight the increasing importance of genomic profiling in drug development and clinical diagnostics. The expansion of the commercial agreement with Tempus AI, Inc. (Tempus) to authorize Tempus to sell NeXT Personal to pharmaceutical and biotechnology companies is a significant development.

Comparison to Industry Standards

• Personalis' revenue growth of 15% for the full year 2024 is a solid performance in the competitive genomics market.
• Companies like Exact Sciences and Guardant Health, which also focus on cancer diagnostics, have seen varying growth rates, making it difficult to directly compare without deeper analysis of specific market segments.
• The $50 million investment from Merck is a strong validation of Personalis' technology and potential, similar to how other genomics companies have secured partnerships and investments from pharmaceutical giants.
• Personalis' focus on MRD testing positions it in a rapidly growing area, as early detection and monitoring of cancer recurrence become increasingly important.

Related Party Transactions

• Related party revenue of $2.0 million for three and twelve months ended December 31, 2024.
• Related party sales and marketing expenses of $0.2 million and $0.5 million for the three and twelve months ended December 31, 2024, respectively.
• Related party other expense of $18.3 million in connection with the change in fair value of Tempus Warrants for the twelve months ended December 31, 2024.
• Related party accounts receivable of $2.5 million as of December 31, 2024.
• Related party liabilities of $1.7 million as of December 31, 2024.
• Related party liabilities of $1.2 million as of December 31, 2024.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and strategic partnerships, but concerned about the projected net loss and increased cash usage in 2025.
• Employees may benefit from the company's growth and expansion, but could face uncertainty due to the projected financial challenges.
• Customers may see improved products and services through the company's investments in technology and partnerships.
• Suppliers may experience increased demand as the company expands its operations.

Next Steps

• Personalis will host a conference call to discuss the fourth quarter and full year 2024 financial results and plans for 2025.
• The company will continue to focus on expanding clinical studies and investing in commercial capabilities to drive growth.
• Personalis aims to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient.

Key Dates